"Next Generation" antisense therapies for eye, inflammatory and cancer diseases

Isarna Therapeutics isarna-therapeutics.com

Invested since 2005

The development of innovative drugs for the targeted treatment of ocular diseases, fibrosis and cancer form the research core of ISARNA. The antisense compound ISTH0036 (ophthalmology) has successfully completed Phase I clinical development and is about to enter more advanced studies for various ocular diseases.

 

Research and clinical development of proprietary antisense agents that specifically inhibit the various isoforms of the key pathogenic protein TGF-beta (transforming growth factor beta).

 

 

Milestones
MIG invests in Isarna 2005
Back to portfolio